

LAHIVE

&

COCKFIELD

L L P

COUNSELLORS AT LAW

28 STATE STREET

BOSTON, MASSACHUSETTS 02109-1784

TELEPHONE (617) 227-7400

FAX (617) 742-4214

lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
RALPH A. LOREN
GIULIO A. DeCONTI, JR.
ANN LAMPORT HAMMITTE
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
PETER C. LAURO
JEANNE M. DIGIORGIO
DEBRA J. MILASINCIC, Ph.D.
DAVID J. RIKKERS
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER

CYNTHIA L. KANIK, Ph.D.
MEGAN E. WILLIAMS, Ph.D.
RICHA NAND
MICHAEL PHILLIPPS *
LISA M. DiROCCO
HATHAWAY P. RUSSELL **
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.
PETER A. DIMATTIA
VINCENT P. LOCCISANO
MERIDETH C. ARNOLD

SENIOR COUNSEL
JAMES E. COCKFIELD

CF COUNSEL
JEREMIAH LYNCH
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPPERT

PATENT AGENTS
THEODORE R. WEST
SHAYNE Y. HUFF, Ph.D.
DANIEL B. KO

TECHNICAL SPECIALISTS
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.
EUIHOON LEE
JENNIFER K. ROSENFELD
ALLAN TAMESHTIT, Ph.D.
CATHERINE E. McPHERSON
ERIC F. WAGNER, Ph.D.
SHAHID HASAN, Ph.D.
JACOB G. WEINTRAUB
JONATHAN M. SPARKS, Ph.D.
CRISTIN E. HOWLEY, Ph.D.

* Admitted in NY only
** Admitted in TX only

August 16, 2002

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Patent Application No.: 09/805,800
*Use of Rapamycin and Agents that Inhibit B7
Activity in Immunomodulation*
Inventor: Joseph Sypek et al.
Filed: March 13, 2001
Our Ref. No.: GNN-018CP

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form 1449;
3. Copies of references cited in PTO Form 1449(34);
4. A copy of the International Search Report; and
5. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

August 16, 2002

Date

Meg E Williams

Megan E. Williams, Esq. Reg. No. 43,270

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

Meg E Williams
Megan E. Williams, Esq.
Registration No. 43,270
Attorney for Applicants

RECEIVED

AUG 21 2002

TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Joseph Sypek et al.

Serial No.: 09/805,800

Filed: March 13, 2001

For: *Use of Rapamycin and Agents that Inhibit B7 Activity in Immunomodulation*

Attorney Docket No.: GNN-018CP

Group Art Unit: 1644

Examiner: P. Gambel

TECH CENTER 1600/29001

AUG 21 2002

RECEIVED

Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

August 16, 2002
Date of Signature and of Mail Deposit

By:

Meg E Williams
Megan E. Williams, Esq.
Registration No. 43,270
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 C.F.R. §1.97 hereby submit these publications for the Examiner's consideration. A full copy of each cited publication is enclosed. In addition, copies of references cited in an International Search Report mailed August 1, 2001 during the prosecution of PCT/US01/08016 which corresponds to the above referenced application, have been enclosed. In accordance with 37 CFR §1.97(b)(3), Applicants hereby submit these publications for the Examiner's consideration

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP



Megan E. Williams, Esq.
Registration No. 43,270
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: August 16, 2002

AEM/MEW/SYH/ipc
Enclosures